Please use this identifier to cite or link to this item: https://hdl.handle.net/20.500.11851/9057
Title: How effective are APRI, FIB-4, FIB-5 scores in predicting liver fibrosis in chronic hepatitis B patients?
Authors: Sapmaz F.P.
Büyükturan G.
Sakin Y.S.
Kalkan İ.H.
Atasoy P.
Keywords: APRI
Chronic hepatitis B
FIB-4
FIB-5
alanine aminotransferase
albumin
alkaline phosphatase
alpha fetoprotein
aspartate aminotransferase
C reactive protein
creatinine
gamma glutamyltransferase
urea
virus DNA
adult
Article
aspartate aminotransferase to platelet ratio index
bilirubin blood level
chronic hepatitis B
clinical decision making
clinical effectiveness
controlled study
cross-sectional study
digestive system disease assessment
disease assessment
erythrocyte sedimentation rate
female
fibrosis index based on 5 factors
Fibrosis-4 Index
glucose blood level
Hepatitis B virus
human
human tissue
leukocyte
liver biopsy
liver fibrosis
major clinical study
male
middle aged
performance measurement system
platelet count
predictive value
receiver operating characteristic
retrospective study
complication
liver cirrhosis
liver function test
pathology
severity of illness index
Hepatitis B, Chronic
Humans
Liver Cirrhosis
Liver Function Tests
Platelet Count
Severity of Illness Index
Issue Date: 2022
Publisher: Lippincott Williams and Wilkins
Abstract: Liver fibrosis is the most important factor in the prognosis and treatment plan of patients with chronic hepatitis B (CHB). Aspartate aminotransferase (AST)-to-platelet ratio index (APRI), fibrosis index based on 4 factors (FIB-4), and fibrosis index based on 5 factors (FIB-5) scores are noninvasive fibrosis markers, and previous comparative studies have shown that they are as effective as liver biopsy in detecting liver fibrosis in different liver diseases. The aim of our study is to investigate whether existing scoring systems are effective in demonstrating fibrosis in CHB patients and to compare the APRI, FIB 4, and FIB 5 scores in differentiating early and advanced fibrosis in 123 patients who underwent liver biopsy for CHB infection. APRI, FIB-4, and FIB-5 scores of patients who underwent liver biopsy due to CHB were calculated by means of calculators and recorded to be compared with liver biopsies in terms of fibrosis scoring. One hundred twenty-three patients who underwent liver biopsy due to chronic hepatitis B were included in the study. APRI (area under the receiver-operating characteristic [ROC] curve 0.728), FIB-4 (area under the ROC curve 0.693) and FIB-5 (area under the ROC curve 0.643) scores were evaluated as significant predictors of advanced fibrosis. The scoring system with the highest positive and negative predictive value was evaluated as FIB-4. APRI, FIB-4, and FIB-5 scoring systems are appropriate scoring systems in the assessment of advanced fibrosis in patients with CHB. Our study is the first to compare APRI, FIB-4, and FIB-5 values in CHB patients, and more comprehensive studies are needed. © 2022 Wolters Kluwer Health, Inc. All rights reserved.
URI: https://doi.org/10.1097/MD.0000000000030488
https://hdl.handle.net/20.500.11851/9057
ISSN: 0025-7974
Appears in Collections:PubMed İndeksli Yayınlar Koleksiyonu / PubMed Indexed Publications Collection
Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection

Show full item record

CORE Recommender

Google ScholarTM

Check

Altmetric


Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.